BC
AMLX icon

Boxer Capital’s Amylyx Pharmaceuticals AMLX Stock Holding History

Boxer Capital’s Portfolio AMLX Stock Details AMLX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-1,500,000
Closed -$2.85M – 71
2024
Q2 		$2.85M Hold
1,500,000
– – 0.15% 49
2024
Q1 		$4.26M Buy
+1,500,000
New +$19.6M 0.21% 48
2023
Q4 		– Sell
-2,084,000
Closed -$38.2M – 54
2023
Q3 		$38.2M Hold
2,084,000
– – 2.03% 18
2023
Q2 		$45M Hold
2,084,000
– – 2.08% 17
2023
Q1 		$61.1M Hold
2,084,000
– – 3% 11
2022
Q4 		$77M Hold
2,084,000
– – 4.06% 8
2022
Q3 		$58.7M Sell
2,084,000
-116,000
-5% -$2.89M 3.3% 8
2022
Q2 		$42.4M Hold
2,200,000
– – 2.68% 14
2022
Q1 		$28.3M Buy
+2,200,000
New +$49.7M 1.45% 22

Other funds holding AMLX

TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
AC
Almitas Capital Santa Monica, California $443M AUM 42.36% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Boxer Capital's AMLX Position: Q3 2024 in Review

Boxer Capital sold out of Amylyx Pharmaceuticals (AMLX) in Q3 2024, closing a stake of 1,500,000 shares — an estimated $2.85M sold.

Boxer Capital first reported a position in AMLX in Q1 2022 and held it in 9 quarters. The position peaked at $77M in Q4 2022. 110 funds tracked by Wall St. Rank hold AMLX as of Q3 2024.

  • Boxer Capital reported no remaining Amylyx Pharmaceuticals position as of Q3 2024 after selling out during the quarter.
  • Boxer Capital sold 1,500,000 Amylyx Pharmaceuticals shares in Q3 2024, an estimated $2.85M.
  • Boxer Capital first reported a position in Amylyx Pharmaceuticals in Q1 2022 and held it in 9 quarters.
  • Boxer Capital's Amylyx Pharmaceuticals position peaked at $77M in Q4 2022.
  • 110 funds tracked by Wall St. Rank held Amylyx Pharmaceuticals as of Q3 2024.

Based on Boxer Capital's 13F filing for Q3 2024, filed 14 Nov 2024.